Application of berberine and doxorubicine mixed preparation in preparation of medicament against doxorubicine cardiac dysfunction or tumor

An anti-tumor drug, anti-doxorubicin technology, used in anti-tumor drugs, drug combinations, pharmaceutical formulations and other directions

Inactive Publication Date: 2011-04-13
JINAN UNIVERSITY
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

But so far, clinical studies have found that there is no preparation that can significantly reduce the myocardial toxicity of doxorubicin without affecting the anti-tumor effect of doxorubicin.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of berberine and doxorubicine mixed preparation in preparation of medicament against doxorubicine cardiac dysfunction or tumor
  • Application of berberine and doxorubicine mixed preparation in preparation of medicament against doxorubicine cardiac dysfunction or tumor
  • Application of berberine and doxorubicine mixed preparation in preparation of medicament against doxorubicine cardiac dysfunction or tumor

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0014] Example 1 Effect of berberine on cardiomyocyte injury induced by doxorubicin

[0015] One-day-old newborn SD suckling mice (provided by the Experimental Animal Center of Southern Medical University) were taken, and the apex of the heart was routinely digested with trypsin (Sigma, USA) to obtain cardiomyocytes according to the existing method.

[0016] Suspend the cells in DMEM (purchased from Gibico) containing 10% fetal bovine serum (purchased from Hyclone) and place at 37°C in 5% CO 2 In the incubator, incubate for 2 hours, and purify the obtained cardiomyocytes. According to 1×10 5 cells / mL were seeded in 96-well plates and cultured for 48 hours. 10 mg doxorubicin (DOX) (Sigma, USA) was dissolved in 5 mL of normal saline, and then diluted with DMEM (purchased from Gibico) medium to obtain a 10 μmol / L doxorubicin working solution. Berberine (Ber) (Sigma, USA) was dissolved in double-distilled water to 4.00 μmol / L working solution, and then diluted in DMEM to 1.00 μ...

Embodiment 2

[0027] Example 2 Effect of berberine on the viability of adriamycin-injured cardiomyocytes

[0028] The apical part of the apex of the SD suckling mouse was taken from 1-day-old newborn mice, and the cardiomyocytes were obtained by trypsinization. Suspend cells in DMEM containing 10% fetal bovine serum at 37°C, 5% CO 2 In the incubator, incubate for 2 hours, and purify the obtained cardiomyocytes. According to 1×10 5 cells / mL were seeded in 96-well plates and cultured for 48 hours. Dissolve doxorubicin injection (DOX) with 5 mL of normal saline, and then dilute with DMEM medium to 10 μmol / L doxorubicin working solution. Berberine (Ber) was dissolved in double distilled water to 4.00 μmol / L working solution, and then diluted to 1.00 μmol / L, 0.25 μmol / L, and 0.625 μmol / L working solution respectively. The purified cardiomyocytes were treated with the following drugs:

[0029] ①Control group: 200μL DMEM

[0030] ②Adriamycin (1 μmol / L) group: 180 μL DMEM+20 μL DOX

[0031] ...

Embodiment 3

[0042] Example 3 Observing the Effect of Berberine on Adriamycin-induced Myocardial Apoptosis

[0043] The apical part of the apex of the SD suckling mouse was taken from 1-day-old newborn mice, and the cardiomyocytes were obtained by trypsinization. Suspend the cells in DMEM (purchased from Gibico) containing 10% fetal bovine serum (purchased from Hyclone) and place at 37°C in 5% CO 2 In the incubator, incubate for 2 hours, and purify the obtained cardiomyocytes. According to 1×10 5 cells / mL were seeded in 96-well plates and cultured for 48 hours. Dissolve doxorubicin injection (DOX) with 5 mL of normal saline, and then dilute with DMEM medium to 10 μmol / L doxorubicin working solution. Berberine (Ber) was dissolved in double distilled water to 4.00 μmol / L working solution, and then diluted to 1.00 μmol / L, 0.25 μmol / L, and 0.625 μmol / L working solution respectively. After 48 hours of culture, cardiomyocytes were treated with the following drugs:

[0044] ①Control group: 2...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of a berberine and doxorubicine mixed preparation in preparation of a medicament against doxorubicine cardiac dysfunction or tumor. The molar concentration ratio of the berberine to the doxorubicine in the medicament is (0.625-4): 1, and the optimal ratio is 1:1. The medicament is an oral preparation or an injection preparation. The combined use of the berberine and the doxorubicine can lighten myocardial damage caused by the doxorubicine, also can play a role in inhibiting myocardial apoptosis caused by the doxorubicine, and does not weaken, even enhance the anti-tumor effect of the doxorubicine at the same time.

Description

technical field [0001] The invention relates to berberine and doxorubicin, in particular to the application of a mixed preparation of berberine and doxorubicin in the preparation of anti-doxorubicin-induced cardiac dysfunction or anti-tumor drugs. Background technique [0002] Doxorubicin is an anti-tumor drug widely used clinically. It has very significant curative effects on leukemia, lymphoma, breast cancer, lung cancer, etc., and is currently one of the most commonly used anti-tumor drugs in clinical practice. The main side effect of doxorubicin is myocardial toxicity, which can not only cause arrhythmia, but also induce progressive cardiomyopathy and congestive heart failure with the accumulation of doses. Since the 1980s, many new advances have been made in the research on the molecular mechanism of adriamycin cardiotoxicity. At present, most studies believe that it is possible that adriamycin can activate endogenous cardiomyopathy through oxidative stress pathways or ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/704A61K31/4375A61P9/00A61P35/00
Inventor 王华东吕秀秀陆大祥王媛戚仁斌
Owner JINAN UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap